IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS

被引：0
|
作者：
Pierola, A. Alfonso [1 ]
Montalban-Bravo, G. [1 ]
Takahashi, K. [1 ]
Jabbour, E. J. [1 ]
Kadia, T. [1 ]
Ravandi, F. [1 ]
Cortes, J. [1 ]
DiNardo, C. [1 ]
Daver, N. [1 ]
Borthakur, G. [1 ]
Pemmaraju, N. [1 ]
Konopleva, M. [1 ]
Bueso-Ramos, C. [2 ]
Pierce, S. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Hematopathol, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P665
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [41] Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents
    Bravo, Guillermo Montalban
    Jabbour, Elias
    Kadia, Tapan M.
    Ravandi, Farhad
    Estrov, Zeev E.
    Naqvi, Kiran
    Sasaki, Koji
    Chien, Kelly S.
    Gonzalez, Graciela M. Nogueras
    Dong, Xiao Qin
    Faderl, Stefan
    Schneider, Heather
    John, Rosmy B.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [42] Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
    Montalban-Bravo, Guillermo
    Carcia-Manero, Guillermo
    Short, Nicholas J.
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [43] PATTERNS OF CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS
    Faria, C.
    Chang, E.
    Powers, A.
    Cherepanov, D.
    Broder, M.
    VALUE IN HEALTH, 2012, 15 (04) : A228 - A228
  • [44] LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents
    Chien, Kelly S.
    Class, Caleb A.
    Montalban-Bravo, Guillermo
    Wei, Yue
    Sasaki, Koji
    Naqvi, Kiran
    Ganan-Gomez, Irene
    Yang, Hui
    Soltysiak, Kelly A.
    Kanagal-Shamanna, Rashmi
    Do, Kim-Anh
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1493 - 1499
  • [45] Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
    Duchmann, Matthieu
    Yalniz, Fevzi F.
    Sanna, Alessandro
    Sallman, David
    Coombs, Catherine C.
    Renneville, Aline
    Kosmider, Olivier
    Braun, Thorsten
    Platzbecker, Uwe
    Willems, Lise
    Ades, Lionel
    Fontenay, Michaela
    Rampal, Raajit
    Padron, Eric
    Droin, Nathalie
    Preudhomme, Claude
    Santini, Valeria
    Patnaik, Mrinal M.
    Fenaux, Pierre
    Solary, Eric
    Itzykson, Raphael
    EBIOMEDICINE, 2018, 31 : 174 - 181
  • [46] Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA)
    Duchmann, Matthieu
    Braun, Thorsten
    Platzbecker, Uwe
    Ades, Lionel
    Sebert, Marie
    Dreyfus, Francois
    Park, Sophie
    Vey, Norbert
    Rauzy, Odile Beyne
    De Botton, Stephane
    Micol, Jean-Baptiste
    Berthon, Celine
    Guieze, Rornain
    Bastie, Jean-Noel M.
    Solary, Eric
    Fenaux, Pierre
    Itzykson, Raphael
    BLOOD, 2015, 126 (23)
  • [47] CC-486 in Patients with Myelodys plastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response
    Savona, Michael R.
    Kolibaba, Kathryn
    Conkling, Paul
    Kingsley, Edwin C.
    Becerra, Carlos
    Morris, John
    Rifkin, Robert M.
    Laille, Eric
    Kellerman, Amy
    Ukrainskyj, Stacey M.
    Dong, Qian
    Skikne, Barry S.
    BLOOD, 2014, 124 (21)
  • [48] HYPOMETHYLATING AGENTS DOES NOT IMPROVE OVERALL SURVIVAL IN PATIENTS DIAGNOSED WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) COMPARED TO HISTORICAL DATA
    Affakara, D.
    Hanson, C.
    Swedeh, A.
    Elliott, M.
    Hashmi, S.
    Wolanskyj, A.
    Hogari, W.
    Litzow, M.
    Al-Kali, A.
    HAEMATOLOGICA, 2013, 98 : 88 - 88
  • [49] A RETROSPECTIVE VALIDATION OF INTERNATIONAL CONSORTIUM FOR MDS/MPN RESPONSE CRITERIA IN CMML TREATED WITH HYPOMETHYLATING AGENTS
    Duchmann, M.
    Braun, T.
    Micol, J. B.
    Platzbecker, U.
    Park, S.
    Pilorge, S.
    Beyne-Rauzy, O.
    Vey, N.
    Sebert, M.
    Gruson, B.
    Dumas, P. Y.
    Guieze, R.
    Chretien, M. L.
    Laribi, K.
    Chait, Y.
    Legros, L.
    Hirsch, P.
    Solary, E.
    Fenaux, P.
    Itzykson, R.
    LEUKEMIA RESEARCH, 2017, 55 : S30 - S31
  • [50] Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Saif, MW
    Hopkins, JL
    Gore, SD
    LEUKEMIA & LYMPHOMA, 2002, 43 (11) : 2083 - 2092
12345